SubsidieMeestersA simple blood test to choose the best treatment for each patient with depression.
RxMine uses stem cell technology and machine learning to personalize antidepressant treatment, aiming to significantly reduce healthcare costs and improve patient outcomes for major depressive disorder.
Projectdetails
Introduction
Major depressive disorder affects around 300 million people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to €170 billion to the EU.
Current Treatment Landscape
Despite numerous available drugs, the following issues persist:
- 75% of patients do not receive adequate treatment.
- 63% try multiple medications.
- A third do not respond after two rounds of treatment.
This trial-and-error approach is destructive to patients, time-consuming for physicians, and expensive for health care systems.
RxMine Solution
RxMine revolutionizes this process by combining innovative technologies:
- Stem cell technology
- Genetics
- Neurobiology
- High-throughput screening
- Machine learning
These technologies are used to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model.
Expected Outcomes
RxMine identifies the optimal antidepressant for each patient and potentially reduces:
- Hospitalizations by 89%
- Emergency-room visits by 71%
- Depression-related healthcare costs by 40%
This could lead to savings of up to €6,000 per patient per year.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.000 |
| Totale projectbegroting | € 3.570.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 31-5-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- GENETIKAPLUS LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Autonomous robotics and digital TWIN to improve water network performancesThe project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model. | EIC Accelerator | € 2.478.210 | 2024 | Details |
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming systemToopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability. | EIC Accelerator | € 2.396.457 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Autonomous robotics and digital TWIN to improve water network performances
The project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model.
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming system
Toopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Subtype as a key to reduce heterogeneity of treatment effects in major depressive disorderSUBTREAT aims to enhance treatment for major depressive disorder by identifying subtypes through advanced data science, exploring their causes, and developing predictive algorithms for tailored therapies. | ERC STG | € 1.500.000 | 2022 | Details |
Focused Ultrasound Personalized Therapy for the Treatment of Depression (UPSIDE)The UPSIDE project aims to develop a minimally invasive hybrid neurotechnology for targeted brain stimulation and biomarker monitoring to enhance treatment for Treatment-Resistant Depression. | EIC Pathfinder | € 4.149.921 | 2022 | Details |
Bidirectional Brain/Neural-Computer Interaction for Restoration of Mental HealthThis project aims to develop a portable neuromodulation system using quantum sensors and magnetic stimulation to precisely target brain oscillations for treating mental health disorders. | ERC COG | € 1.999.875 | 2025 | Details |
Identifying the Fast-acting Antidepressant Signatures of Treatment Response with psychedelic compounds using a novel behavioral tracking system and single-cell resolutionFASTer aims to revolutionize behavioral neuroscience by using advanced tracking and molecular techniques to identify brain circuits and genes involved in the rapid antidepressant effects of psilocybin. | ERC STG | € 1.500.000 | 2024 | Details |
Subtype as a key to reduce heterogeneity of treatment effects in major depressive disorder
SUBTREAT aims to enhance treatment for major depressive disorder by identifying subtypes through advanced data science, exploring their causes, and developing predictive algorithms for tailored therapies.
Focused Ultrasound Personalized Therapy for the Treatment of Depression (UPSIDE)
The UPSIDE project aims to develop a minimally invasive hybrid neurotechnology for targeted brain stimulation and biomarker monitoring to enhance treatment for Treatment-Resistant Depression.
Bidirectional Brain/Neural-Computer Interaction for Restoration of Mental Health
This project aims to develop a portable neuromodulation system using quantum sensors and magnetic stimulation to precisely target brain oscillations for treating mental health disorders.
Identifying the Fast-acting Antidepressant Signatures of Treatment Response with psychedelic compounds using a novel behavioral tracking system and single-cell resolution
FASTer aims to revolutionize behavioral neuroscience by using advanced tracking and molecular techniques to identify brain circuits and genes involved in the rapid antidepressant effects of psilocybin.